Bliss GVS Pharma logo

Bliss GVS Pharma financials: balance sheet, profit and loss, cash flow

NSE: BLISSGVSBSE: 506197Pharmaceuticals & BiotechnologySmall Cap

Bliss GVS Pharma Limited · Face value ₹1 · Listed Oct 1985 on BSE, Jul 2010 on NSE
Last close ₹647.50down ₹33.40 (4.91%)BSE ₹648.40

Share price at the NSE close on 30 Oct 2026. Previous close ₹680.90.

30 Oct: open ₹660.00, high ₹670.00, low ₹646.90

52-week range of traded prices to 30 Oct 2026
₹118.00Low, 10 Nov 2025₹739.90High, 28 Sep 2026
Market cap
₹6,885 Cr1,000th largest listed
P/E
42.71
P/B
5.34
Dividend yield
0.23%
ROE
13.3%
ROCE
14.9%
Debt to equity
0.00
Volume, NSE
4,45,760

Bliss GVS Pharma's financial statements for the 10 years to Mar 2026, consolidated: the company and its subsidiaries together, with the half year to Sep 2026 after them. It had no borrowings at 30 Sep 2026.

10 years at a glance

₹ crore, years to March.Bliss GVS Pharma annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
80086Mar 1781589Mar 1889812797Mar 1968995104Mar 205777498Mar 2174723105Mar 227527798Mar 237708288Mar 248109071Mar 259271352.9Mar 26
Peak revenue ₹927 Cr, year to Mar 2026; lowest ₹577 Cr, year to Mar 2021

Operating and net margin, per cent

  • Operating margin
  • Net margin
24.2%3.1%24.2%24.2%17.6%17.9%18.5%15.8%15.6%19.6%15.6%17.7%10.7%10.9%14.1%13.8%12.8%3.1%10.2%10.6%11.1%14.5%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 2.1% of operating profit in the first full year.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue927
  2. Materials and goods−425
  3. Employee costs−136
  4. Other expenses−202
  5. Operating profit164
  6. Depreciation−33
  7. Other income+74
  8. One-off items−2.5
  9. Finance costs−12
  10. Profit before tax190
  11. Tax−55
  12. Net profit135

What the company owns

  • Plant, investments and other assets₹656 Cr
  • Receivables₹517 Cr
  • Cash and bank₹167 Cr
  • Inventory₹151 Cr
  • Current investments₹1 Cr

What pays for it: net worth and liabilities

  • Net worth₹1,232 Cr
  • Other liabilities₹154 Cr
  • Owed to suppliers₹104 Cr
  • Borrowings₹3 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Sep 2026, the latest four quarters added.Bliss GVS Pharma quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 12 MaySep 2026Twelve monthsFiled 29 Oct
Revenue from operations8008158986895777477527708109271,074
606618741566471629634620683763838
Materials and goods bought359391612440329391401382414425449
Employee costs6169425468768696112136160
Other expenses186157867274162147142157202229
Operating profit before depreciation194197158123107118117151127164236
Operating margin24.2%24.2%17.6%17.9%18.5%15.8%15.6%19.6%15.6%17.7%22.0%
Materials, % of revenue44.9%48.0%68.2%63.8%57.0%52.3%53.4%49.6%51.1%45.8%41.8%
Employee costs, % of revenue7.6%8.5%4.7%7.8%11.8%10.2%11.5%12.4%13.8%14.7%14.9%
Other expenses, % of revenue23.3%19.3%9.6%10.5%12.7%21.7%19.5%18.4%19.4%21.7%21.3%
Depreciation and amortisation202191317171926293337
Operating profit after depreciation174176149111891019912497131199
Other income2627383720311829367448
Finance costs202345651078127
Profit before one-off items and tax179179182142104128106146126192239
One-off items0−340−130−740−290−2−2
Profit before tax17914518212910454106117126190236
6357553430312935355570
8689127957423778290135166
Other comprehensive income––−24−1−7−65−22−3
Total comprehensive income––125997316708688137164
Net margin10.7%10.9%14.1%13.8%12.8%3.1%10.2%10.6%11.1%14.5%15.5%
Belonging to the company's shareholders is left blank for the year to Mar 2018: the filing's earnings per share does not match the profit it states, and cannot be multiplied back into the owners' profit because the share it leaves the other owners is more than 10 points from the share the company's other periods state.

Balance sheet

Consolidated, ₹ crore, at 31 March. The last column is the half year to Sep 2026, after the latest full year: the balance sheet at its end.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 12 MaySep 2026Half yearFiled 29 Oct
6607508288469171,0031,0921,2321,331
6467368088198849671,0501,1931,290
Share capital101010101010111111
Reserves6367257988088739571,0401,1821,280
Belonging to outside owners of subsidiaries141520283436413941
971049810598887130
207232204233193160172236230
384645294651372521
9051,0291,0771,1091,1571,2141,3011,4921,582
211256312333459402474546583
694773765776697812819946999
Net debt−100−47−73−10−128−142−165−151
Borrowings are counted again inside the liabilities due within a year and after a year. Plant in use and plant being built are given for full years only. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March. The last column is the half year to Sep 2026, after the latest full year: the cash flow over its six months.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 12 MaySep 2026Half year
641353415210613936
931697918714318173
−5874−853−51−104−119
Receivables6351−15−45−45−88−81
Inventories−27−2915−22−30−45−40
Payables−1518−6−25113319
Other working capital−7934−799513−3−16
Tax paid−290−45−35−37−42−35
Interest paid0−3400000
Capital spending909428765732
Free cash flow55135−5912430824
−47−93−8−133−75−38−15
−21−24−25−21−30−89−19
Dividends paid655551111
Shares bought back0000000
Shares issued0222322
Net change in cash−4192−10112
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Bliss GVS Pharma dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 12 May
Earnings per share₹8.30₹5.70₹11.99₹9.43₹6.64₹1.46₹6.83₹7.23₹8.02₹12.23
Diluted earnings per share₹8.30₹5.70₹11.99₹9.43₹6.49₹1.43₹6.72₹7.11₹7.95₹12.00
Dividend per share₹0.60₹1.00₹1.00₹0.50₹0.50₹0.50₹0.50₹0.50₹0.50₹1.50
Book value per share––₹62.63₹71.32₹78.36₹78.97₹84.87₹92.39₹99.68₹112.76
Dividend payout7.2%–8.3%5.3%7.5%34.5%7.3%6.9%6.2%12.3%
Shareholder yield––––0.5%0.4%0.5%0.3%0.2%0.4%
Market cap at the year end (₹ crore)1,8222,0291,8511,0391,0177997411,1811,2412,281

Ratios

Consolidated, years to March.Bliss GVS Pharma PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 12 May
Revenue growth46.2%1.9%10.2%−23.3%−16.3%29.5%0.6%2.5%5.1%14.5%
Operating profit growth–1.8%−20.0%−21.8%−13.5%11.0%−0.9%28.4%−15.9%29.5%
Net profit growth3.8%3.6%42.9%−24.8%−22.3%−68.7%231.8%6.3%10.6%49.3%
Earnings per share growth–−31.3%110.4%−21.4%−29.6%−78.0%367.8%5.9%10.9%52.5%
––19.2%14.1%8.9%1.8%8.3%8.2%8.4%11.5%
–––−5.1 pts−5.2 pts−7.0 pts6.5 pts−0.2 pts0.2 pts3.2 pts
From the net margin–––0.5 pts−2.2 pts−7.4 pts6.8 pts0.3 pts0.5 pts2.8 pts
From asset turnover–––−5.5 pts−2.7 pts0.4 pts−0.3 pts−0.2 pts−0.1 pts0.3 pts
From borrowing–––0.0 pts−0.2 pts0.0 pts−0.1 pts−0.3 pts−0.2 pts0.0 pts
Return on capital employed––19.7%13.0%9.7%10.6%9.7%11.4%8.4%10.6%
Cash conversion––––86.5%585.8%44.7%186.9%117.3%103.0%
Interest cover8.77.733.720.516.221.39.518.012.010.9
Debt to equity––0.150.140.120.120.110.090.070.00
Receivable days––187290293192187192198204
Inventory days––466211011694113111129
Payable days––4778828679586389
Cash conversion cycle, days––186274321221202247246244
Working capital days––181267305218220231219215
Asset turnover––0.990.710.550.680.660.650.640.66
Assets per rupee of net worth––1.401.401.361.341.331.281.251.25
Sales per rupee of plant––6.662.962.562.742.032.132.042.06
Capital spending to depreciation––––0.530.005.021.072.591.70
Plant being built, % of plant in use––34.7%0.0%1.1%8.1%0.8%2.2%5.2%1.3%
No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
9.2%
Cash from operations against operating profit
84.6%
Measure10 years5 years3 years
Revenue growth, yearly rate5.4%9.9%7.2%
Profit growth, yearly rate4.6%13.5%22.1%
Return on equity, average–7.6%9.3%
Return on capital employed, average–10.1%10.1%
Operating margin, average18.7%16.9%17.6%
Net margin, average11.2%9.9%12.1%
Asset turnover, average–0.660.65
Cash conversion cycle, days, average–232245
Interest cover, average15.814.313.6
Debt to equity, average–0.080.05

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations567397139
Cash from investing−347−247−38
Cash from financing−189−140−89
Capital spending25516157
Dividends paid322211
Shares bought back000
Shares issued for cash1172
Borrowings raised126754
Borrowings repaid24116064

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––664767
Altman Z-scorePublished threshold 1.81––7.834.964.994.294.426.086.248.00
Beneish M-scorePublished threshold −1.78––––−1.68−3.26−2.05−2.96−2.02−2.36
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––5.41−1.774.435.234.752.46
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––1.341.781.181.30
Receivables growth less revenue growthOur threshold 0 percentage points–––42.180.92−44.82−2.482.503.293.49
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––23.9658.686.41−19.4919.71−2.1117.14
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––−0.171.793.202.58−3.70−3.797.35
Assets under construction, years of additionsOur threshold 2 years of additions–––0.000.240.340.020.440.320.07
Effective tax ratePublished threshold 17.16 per cent35.0738.9730.3726.1428.9657.3027.6630.2028.1628.94
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––57.30−14.350.38−1.006.97
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
5 Jun 2026CRISIL Ratings LimitedBank FacilitiesCrisil A4/Issuer Not Cooperating (Withdrawn)Review, Other10
5 Jun 2026CRISIL Ratings LimitedBank FacilitiesCrisil B/Stable/Issuer Not Cooperating (Withdrawn)Review, OtherStable35
2 Jun 2026ICRA LimitedFund-based/Non-fund based-Others[ICRA]A- Rating Watch with Developing Implications/[ICRA]A2+ Rating Watch with Developing ImplicationsReview, Other100
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.